Purpose:Allergicrhinitis(AR)isregardedasariskfactorforasthmaandbronchialhyperresponsiveness(BHR)isfrequentlyobserved
INTRODUCTION
Allergic rhinitis (AR) is characterized by typical symptoms induced by nasal immunoglobulin E (IgE)-mediated inflammatory response after allergen exposure. 1) Symptoms of AR can affect quality of life more than symptoms of asthma do, 2) and the prevalence in children reaches 23.4% to 31.2%. 3, 4) Asthma and AR are known to be closely related, 5) and AR is regarded as a risk factor for the incidence of asthma. 6) Since AR often precedes or is associated with asthma, the World Health Organization document, "Allergic Rhinitis and its Impact on Asthma (ARIA)," 7) emphasized the role of AR as a risk factor in the development of asthma and recommended exploration of bronchial involvement in patients with AR.
As abnormalities of spirometric parameters are exhibited by AR patients without asthma, impaired values of forced expiratory volume in 1 second (FEV1) can be detected, 3) and airway reversibility evidenced by increased FEV1 after a bronchodilator test has been reported. 8) AR patients are also reported to have reduced forced expiratory flow between 25% and 75% of vital capacity (FEF25-75) as an early marker of bronchial damage. 9) These findings are suggestive of bronchial involvement and damage in patients with AR without obvious symptoms of asthma. In addition, nasal lavage of asthmatic children showed Th2 polarization, which confirmed there is a pathophysiologic link between the upper and lower airway. 10) It also has been reported that there is an association between nasal allergic inflammation maintained by eosinophil infiltration and bronchial obstruction indicated by an reduced FEV1.
11)
Bronchial hyperresponsiveness (BHR) to natural stimuli such as exercise or chemical stimuli such as histamine or methacholine is a characteristic feature of asthma, 12) and it is associated with an inflammatory response in the lower respiratory tract in patients with asthma. 13) BHR is observed in more than one third of AR patients, [14] [15] [16] and children with AR are more likely to have BHR compared to children without AR. 4) BHR to methacholine among rhinitics is associated with subclinical asthma, 17) and AR patients with BHR are at significantly higher risk of developing asthma compared to patients with normal bronchial provocation test results. 18) Factors that can affect the development of BHR in patients with AR include nasal inflammation, 19) the duration of AR, 20) positive skin prick test (SPT) reactions to a larger number of allergens, 14) total IgE levels, 21) sputum eosinophil counts, 22) perennial type of rhinitis, 15) low FEF25-75, 23) low FEF25-75/forced vital capacity (FVC) ratio, 24) positive bronchodilation test results, 25) a family history of asthma 15) and a family history of BHR. 26) There has been a lot of researches on the predictors of BHR in patients with AR but this is the first time in Korean pediatric patients with short duration of AR and relatively good lung function compared to patients with asthma. The purpose of this study is to analyze the characteristics of AR patients with BHR who are thought to be at a higher risk of developing asthma compared with those without BHR and to identify factors that contribute to the incidence of BHR.
MATERIALS AND METHODS

Subjects
The Severance Hospital Institutional Review Board approved this study, and informed consent was obtained from the parents of the children. (Blatella germanica). After dropping the allergen solutions on the children's backs, a skin prick was performed using 26 G needles.
Histamine and isotonic solution were used as positive and negative controls, respectively, and an average wheel diameter greater than 3 mm measured 15 minutes after performing the test was defined as positive. A positive SPT response for one or more allergens was also defined as atopy.
Spirometry and methacholine challenge test (MCT)
Spirometry was performed, short-acting bronchodilator responses were measured to evaluate bronchial reversibility, and
MCTs were performed to evaluate BHR in all patients.
Spirometry was performed using a Jaeger MasterScreen IOS (Jaeger, Wurzburg, Germany). FEV1, FVC, FEV1/FVC, and FEF25-75
were measured before and after bronchodilator inhalation according to the American Thoracic Society guidelines. 27 ) Maximum values among the three FVC maneuvers were recorded. A bronchodilation test was performed using 400 μg of salbutamol. ΔFEV1
was defined as the value of change in percent predicted FEV1 after salbutamol inhalation multiplied by 100 divided by the value of baseline percent predicted FEV1. Likewise, Δ FEF25-75 was defined as the value of change in percent predicted FEF25-75 after salbutamol inhalation multiplied by 100 divided by the value of baseline percent predicted FEV1. The reference values of spirometric parameters were based on the previous paper. 28) MCT was performed according to standardized procedures. The provocative concentration causing a 20% decrease in FEV1
(PC20) was calculated using a dose-response curve. Subjects were considered to have BHR to methacholine if their PC20 was less than 16 mg/mL. The PC20 was recorded as 100 mg/mL unless the FEV1 decreased by more than 20% after inhalation of the maximum methacholine concentration of 50 mg/mL. Logistic regression analysis was used to identify predictive factors for positive BHR. Each variable was first analyzed using univariate regression analysis, and variables with a P-value < 0.1 were included in the multivariate logistic regression model after excluding multicollinearity. Odds ratio (OR) and 95% confidence interval (CI) were obtained for the selected variables, and the results were adjusted for age and gender.
Statistical analysis
A receiver operating characteristics (ROC) curve was generated to test the validity of FEF25-75 as a means to distinguish between positive and negative BHR subjects, and the area under the curve (AUC) and its 95% CI were calculated. The cutoff value was obtained from the curve using the Youden method. Patients were subsequently divided into two groups according to the cutoff value and the frequency of BHR was compared between groups with the chi-square test. P-values < 0.05 were considered statistically significant, and statistical analyses were done using PASW ver. 18.0 (IBM Co., Armonk, NY, USA).
RESULTS
Among a total of 176 patients, 155 patients (88%) were classified as the BHR-negative group and 21 patients (12%) were classified as the BHR-positive group. Table 1 Table 2 . FEF25-75 %predicted (OR, 0.973; 95% CI, 0.948 to 1.000; P = 0.046) was the only variable found to be statistically significant. Fig. 1 shows the ROC curve of FEF25-75 for predicting the presence of BHR. The AUC was 0.669 (95% CI, 0.543 to 0.794; P = 0.012) and the optimal cutoff value for distinguishing patients with BHR was 88.4%. Table 3 shows a comparison of the frequency of BHR between the two groups divided based on this cutoff value. A higher frequency of BHR was found in the group with an FEF25-75 less than 88.4% (P < 0.0001), and the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 57.1%, 80.6%, 28.6%, and 93.3%, respectively.
DISCUSSION
AR and asthma can be considered one disease taking place in two parts of the respiratory system. 29) Airway reversibility to a bronchodilator 16) and BHR, 14, 23) The frequency of BHR in each group was compared with the chi-square test. BHR, bronchial hyperresponsiveness; FEF25-75, forced expiratory flow between 25% and 75% of vital capacity. Fig. 1 . Receiver operating characteristics curve of forced expiratory flow between 25% and 75% of vital capacity as a diagnostic test for bronchial hyperresponsiveness. The area under the curve was 0.669 (95% confidence interval, 0.543 to 0.794; P= 0.012) and the optimal cutoff value to distinguish patients with bronchial hyperresponsiveness was 88.4%. 57.1%, specificity of 80.6%, PPV of 28.6% and NPV of 93.3%.
Even though some studies showed that residual volume/total lung capacity ratio indicating that the degree of hyperinflation reflected the severity of airway obstruction, 30) FEF25-75 is thought to correspond to the peripheral airway caliber and has been proposed as a more sensitive parameter than the FEV1 for assessing the presence of a small airway obstruction. 31) A low FEF25-75 in the setting of a normal FEV1 is associated with increased asthma severity, systemic steroid use, and asthma exacerbations in children. 32 ) Impaired FEF25-75 has been reported as a marker of early bronchial pathology in patients with AR, 9) and studies on the significance of this parameter have also been done in rhinitics. has been reported to decrease significantly as the duration of AR increases, 33) and another study proposed that a greater than 40%
decrease in FEF25-75 may be a more useful tool to assess BHR in MCT rather than a 20% decrease in FEV1 in patients with AR.
34)
Impaired FEF25-75 less than 65% of the predicted value was a predictive of severe BHR (PC20 <1 mg/mL) in adolescents with AR, 35) and the best FEF25-75 cutoff value to distinguish patients with both airway reversibility and severe BHR was reported to be 58.5% in a study of adults patients with AR. 25) The value of FEF25-75 with the greatest sensitivity and specificity to detect a 20% increase in FEV1
was 68% in a study conducted in asthmatic children. 36) The optimal cutoff value of FEF25-75 to predict the presence of BHR was 88.4% in the present study. This cutoff value is relatively high compared to previous studies and this is thought to be due to the differences in study subjects' characteristics and outcome. In this study, the median age of the BHR-negative group and BHR-positive group was less than 10 and children with short duration AR compared with adults were only included. 37) The subjects of this study had relatively good lung function while previous studies examined adults with longer duration AR or asthmatic children. In addition, outcomes of previous studies were severe BHR (PC20 <1 mg/mL) 23) or both airway reversibility and severe BHR 25) whereas the outcome of this study was BHR (PC20 <16 mg/mL).
In this study, 12% of the total subjects showed positive BHR.
Previous studies showed a high frequency of BHR ranging from 39% to 62%, 14, 19) and in a study of the general population from 8 to 73 years old, BHR-positive rate of 26% was demonstrated. 38) The results of the present study is thought to be due to differences in the subjects' characteristics.
One of the limitations of this study is that patients were retrospectively reviewed based on medical records without follow-up.
Longitudinal studies are needed to confirm the conclusion that patients with only AR and low FEF25-75 have a higher risk of BHR and they actually are likely to present with asthmatic symptoms in the future. In addition, it will be shown whether the shifting from BHR-negative to BHR-positive group in children with AR can occur through longitudinal studies. Since AR and asthma frequently exist simultaneously, 39) it was important to exclude subjects with undetected asthma, which coexists with AR, by examining their medical records thoroughly to screen for symptoms suggestive of asthma. However, the retrospective review was limited. In addition, according to previous studies, patients with perennial rhinitis had a higher risk of BHR than patients with seasonal rhinitis 15) and BHR increased two-fold during pollen season in patients with seasonal AR, 40) suggesting the type of AR and seasonality could affect BHR. Moreover, the duration of AR can affect the degree of BHR, but these factors were not identified in the patients' medical records and were therefore not considered in the analysis.
In conclusion, the lower airway in patients with AR should be carefully evaluated because they often present with impaired spirometric parameters and BHR. This study emphasizes the role of show BHR and treating and monitoring them appropriately. Additional longitudinal studies and intervention studies to assess the incidence of asthma as an outcome will facilitate the understanding of the mechanism underlying these diseases and enable appropriate evaluation and accurate treatment in each patient.
